Member Info for Vertizea-Sun

What have I missed? Is Novartis shelling out $1B for a theoretical process? In testing?

"Mariana’s lead program, MC-339, is an actinium-based radioligand therapeutic being investigated to treat small cell lung cancer."

Pre|CISION guided therapy hit FAP enveloped tumours in more than 40 trial patients .... a 100% success rate. This is worth a lot of money.

July/August. It will take a deal maker like Simon Bennett 7 or 8 months to get the ball rolling. It doesn't happen overnight.

An FDA encouraged t/o before the end of the year....in my opinion

I wonder what Sherlock would say?

Indeed it is ..... pre|CISION and Affimers only.

All Change. Something is happening next week.

Thank you gmcc for the Glossary. We are being prepped for the exact meaning of "Partial Response" and "Minor Response"

Except Novartis Head of World-Wide Research commended Avacta and pointed out the best is yet to come.

An armchair at full throttle.

Perfect for FAP targeting pre|CISION:

"They found seven tumours in my brain, which were causing my headaches, but further investigation found that my primary cancer was in my lung, where I have three tumours."

The cancer had also spread to Kat's lymph nodes and her skull."

'Works'.

I'm perfectly happy to wait four weeks for the answer. Really not a problem.

Limping along?

RNS 28 February 2024

"10 tumour biopsies obtained from 9 patients in different cohorts have also been analysed in order to confirm the release of the active chemotherapy, doxorubicin, in the tumour tissue. This analysis shows that AVA6000 targets the release of doxorubicin to the tumour tissue at therapeutic levels "

Accidental no doubt but still rather funny.

This is the answer from www.perplexity.ai

To make egg noodles with 300g of flour, you will need approximately 3 large eggs and 1 egg yolk. The general rule is to use 1 large egg for every 100g of flour, and adding an extra egg yolk to the mixture enhances the texture. Therefore, for 300g of flour, you would typically use 3 large eggs and 1 egg yolk

The Circular, including notice of the General Meeting, is expected to be sent to Shareholders and be made available on the Company's website at https://avacta.com/ on or around 1 March 2024.

It is proposed that the General Meeting be held at Walker Morris LLP, 33 Wellington Street, Leeds, LS1 4DL at 11.00 a.m. on 18 March 2024, where the resolution will be proposed to seek authority to issue and allot the new Shares pursuant to the Conditional Placing and the REX Offer.

The updated valuation promised in the RNS from 6 June 23 is still pending:

"The second milestone will result in an increase in Avacta's shareholding in AffyXell, which currently stands at 19%. The exact shareholding will be determined, as with the first milestone payment which was achieved in April 2022, following a formal valuation of AffyXell."

Exactly LDA. 40+ patients successfully administered with pre | CISION and the next step is match that with a suitable warhead. "The best is yet to come"

The rhetoric has been dialled down because Coughlin and Bennett are now running the show and "paradigm" probably embarrassed them. But pre | CISION works.

Quote from last week's RNS:

o Presentation of Phase 1 three-weekly study clinical data at AACR 2024 in April 2024;"

Could go either way.

Today is the last day for Presentation Title submission to ACCR...as promised in last week's RNS and that Title should be on-line tomorrow with the body text due before the 5th April:

"· AVA6000:

o Read out of two-weekly and three-weekly dose escalation study data in late Q2 2024;

o Presentation of Phase 1 three-weekly study clinical data at AACR 2024 in April 2024;"